Alcon Research, Ltd.

Arrowhead Pharmaceuticals, Inc.

Oculeve, Inc.

Diane Michelle Senchyna

John M Yanni

Jon E Chatterton

Daniel A Gamache

Steven T Miller

Manfred Franke

Daniel N Hamilton

Described here are devices, systems, and methods for treating meibomian gland disease and/or blepharitis by providing intranasal stimulation. Generally, the devices may deliver electrical stimulation to the nasal mucosa. Intranasal stimulation may unblock obstructed meibomian glands and increase the lipid content of tears, both acutely during stimulation and subsequent to intranasal stimulation. The methods may include an initial round of stimulation to unblock obstructed meibomian glands, and subsequent shorter rounds of stimulation to cause meibum secretion and maintain the open glands.

Intranasal stimulation for treatment of meibomian gland disease and blepharitis

RNA interference is provided for inhibition of tumor necrosis factor &#x3b1; (TNF&#x3b1;) by silencing TNF&#x3b1; cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNF&#x3b1; converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNF&#x3b1; targets, in particular, is useful for treating patients having a TNF&#x3b1;-related condition or at risk of developing a TNF&#x3b1;-related condition such as the ocular conditions dry eye, allergic conjunctivitis, or ocular inflammation, or such as dermatitis, rhinitis, or asthma, for example.

RNAi-mediated inhibition of tumor necrosis factor &#x3b1;-related conditions

RNAI-mediated inhibition of tumor necrosis factor &#x3b1;-related conditions

Growing community of inventors

Corona Del Mar, CA, United States of America

Diane Michelle Senchyna